Physician
El-Fakharany, Mohamed
El-Fakharany, Mohamed was paid $57K by Medicaid between Oct 2020 and Oct 2024, across 6 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 29% of everything it billed.
33Billing provider infoEL-FAKHARANY, MOHAMED
CANTON, MI 48188
CANTON, MI 48188
33aNPI1225242449assigned 05/09/2007
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$57K
24GClaims4,260
24DCodes billed6
24AFirst – last monthOct 2020 – Oct 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Michigan
Rank by total paid#31 of 51
Median peer was paid$161K
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,556 | $11K | |
| 2021 | 2,592 | $33K | |
| 2023 | 78 | $8K | |
| 2024incomplete | 34 | $4K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 29% | 1,382 | 1,228 | $17K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 27% | 1,537 | 1,353 | $15K |
| 99000 | 22% | 1,058 | 934 | $12K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 22% | 112 | 99 | $12K |
| 99001 | <1% | 14 | 14 | $12.88 | |
| 99072 | 0% | 157 | 149 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.